Ashler et Manson (XPAR:MLAEM) Other Stockholders Equity: €0.20 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MLAEM Ashler et Manson SA XPAR:MLAEM
80 GF Score
Price €3.04
GF Value €2.62
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Ashler et Manson Other Stockholders Equity?

Ashler et Manson XPAR:MLAEM 80 Other Stockholders Equity is €0.20 Mil as of Dec. 2024. GuruFocus rates XPAR:MLAEM with a GF Score™ of 80/100 and a GF Value™ of €2.62 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Ashler et Manson's Other Stockholders Equity for the quarter that ended in Dec. 2024 was €0.20 Mil.

Ashler et Manson's quarterly Other Stockholders Equity declined from Dec. 2022 (€0.29 Mil) to Dec. 2023 (€0.18 Mil) but then increased from Dec. 2023 (€0.18 Mil) to Dec. 2024 (€0.20 Mil).

Ashler et Manson's annual Other Stockholders Equity declined from Dec. 2022 (€0.29 Mil) to Dec. 2023 (€0.18 Mil) but then increased from Dec. 2023 (€0.18 Mil) to Dec. 2024 (€0.20 Mil).

Ashler et Manson Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ashler et Manson's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ashler et Manson Other Stockholders Equity Chart

Ashler et Manson Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.18 0.29 0.18 0.20

Ashler et Manson Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.18 0.29 0.18 0.20
XPAR:MLAEM
80GF Score
Ashler et Manson SA XPAR:MLAEM
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ashler et Manson Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.20 Mil mean?
Ashler et Manson (XPAR:MLAEM) has a Other Stockholders Equity of €0.20 Mil as of Dec. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ashler et Manson and its competitors.
Is Ashler et Manson's Other Stockholders Equity too high?
Ashler et Manson's current Other Stockholders Equity is €0.20 Mil. Overall, Ashler et Manson has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ashler et Manson's Other Stockholders Equity compare to MRSH and AON?
Ashler et Manson's Other Stockholders Equity of €0.20 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for an Insurance company?
A good Other Stockholders Equity depends on the Insurance industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ashler et Manson and its competitors. Ashler et Manson's current Other Stockholders Equity is €0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ashler et Manson stock overvalued right now?
Based on GuruFocus' analysis, Ashler et Manson (XPAR:MLAEM) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.62, compared to a current price of €3.04 — trading 16% above its estimated fair value. The current Other Stockholders Equity is €0.20 Mil. Ashler et Manson's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Ashler et Manson (XPAR:MLAEM), the current Other Stockholders Equity is €0.20 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ashler et Manson (XPAR:MLAEM) Overvalued in 2026?

Based on GuruFocus' analysis, Ashler et Manson stock appears to be overvalued. The current stock price of €3.04 is trading 16% above its estimated GF Value™ of €2.62. GuruFocus considers Ashler et Manson to be Modestly Overvalued.

Key valuation signals for XPAR:MLAEM:

  • Other Stockholders Equity: €0.20 Mil
  • GF Value™: €2.62 vs. price of €3.04 (16% above fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the XPAR:MLAEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ashler et Manson Business Description

Address 2 Allees d'Orleans, Bordeaux, FRA, 33000
Ashler et Manson SA is a France-based brokerage group in real estate credit and loan insurance sector.
80GF Score

Get the complete analysis for XPAR:MLAEM

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€2.62
GF Value